| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Institute of Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.
a Author for correspondence. Fax 41-1-255-4590; e-mail hmr{at}ikc.unizh.ch
Background: Interindividual differences in CYP2D6 activity range from total absence of metabolism of certain drugs to ultrafast metabolism and can produce adverse effects or lack of therapeutic effect under standard therapy. Several mutations have been described in the CYP2D6 gene that abolish CYP2D6 activity. However, four mutations explain the majority of the poor metabolizers. We describe four single-tube assays to detect these mutations.
Methods: Three tetra-primer PCR assays were developed to detect the mutations in the CYP2D6*3, *4, and *6 alleles. In these single-tube assays, the CYP2D6 locus is amplified directly, followed by the allele-specific amplification on this new template. In addition, a multiplex long PCR was developed to genotype the CYP2D6*5 allele. Two long PCR amplifications for detection of the deletion of CYP2D6 (*5) and for detection of the CYP2D6 gene region were combined in one tube.
Results: Analysis of 114 alleles showed no CYP2D6*3 allele, and allele frequencies of 28.1% for CYP2D6*4, 2.6% for CYP2D6*5, and 0.9% for CYP2D6*6. Re-analysis of the DNA samples by restriction fragment length polymorphism and sequencing analysis confirmed these results. Furthermore, re-analysis of sequenced genomic DNA by tetra-primer PCR analysis (7–11 times) always showed identical results.
Conclusions: Our set of single-tube assays allows rapid and reproducible genotyping of the majority of CYP2D6 poor metabolizers.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  N. Hosono, M. Kato, K. Kiyotani, T. Mushiroda, S. Takata, H. Sato, H. Amitani, Y. Tsuchiya, K. Yamazaki, T. Tsunoda, et al. CYP2D6 Genotyping for Functional-Gene Dosage Analysis by Allele Copy Number Detection Clin. Chem., August 1, 2009; 55(8): 1546 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu, Y. Sun, L. Yao, L. Shi, Y. Wu, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann. Onc., August 1, 2008; 19(8): 1423 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. De Fazio, L. Gallelli, A. De Siena, G. De Sarro, and M. G. Scordo Role of CYP3A5 in Abnormal Clearance of Methadone Ann. Pharmacother., June 1, 2008; 42(6): 893 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Allegaert, J. N. van den Anker, J. N. de Hoon, R. H. N. van Schaik, A. Debeer, D. Tibboel, G. Naulaers, and B. J. Anderson Covariates of tramadol disposition in the first months of life Br. J. Anaesth., April 1, 2008; 100(4): 525 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, L. Yu, A.-P. Zhang, C. Fang, J. Du, N.-F. Gu, S.-Y. Qin, G.-Y. Feng, X.-W. Li, Q.-H. Xing, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia J Psychopharmacol, November 1, 2007; 21(8): 837 - 842. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. van der Lee, A. A. M. Blenke, G. A. Rongen, C. P. W. G. M. Verwey-van Wissen, P. P. Koopmans, C. Pharo, and D. M. Burger Interaction Study of the Combined Use of Paroxetine and Fosamprenavir-Ritonavir in Healthy Subjects Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4098 - 4104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nishizawa, H. Suzuki, A. Umezawa, H. Muraoka, E. Iwasaki, T. Masaoka, I. Kobayashi, and T. Hibi Rapid Detection of Point Mutations Conferring Resistance to Fluoroquinolone in gyrA of Helicobacter pylori by Allele-Specific PCR J. Clin. Microbiol., February 1, 2007; 45(2): 303 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Kootstra-Ros, M. J. M. Van Weelden, J. W. J. Hinrichs, P. A. G. M. De Smet, and J. van der Weide Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J. Clin. Pharmacol., November 1, 2006; 46(11): 1320 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Soderback, A.-L. Zackrisson, B. Lindblom, and A. Alderborn Determination of CYP2D6 Gene Copy Number by Pyrosequencing Clin. Chem., March 1, 2005; 51(3): 522 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jin, Z. Desta, V. Stearns, B. Ward, H. Ho, K.-H. Lee, T. Skaar, A. M. Storniolo, L. Li, A. Araba, et al. CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment J Natl Cancer Inst, January 5, 2005; 97(1): 30 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. M. Stamer, B. Bayerer, S. Wolf, A. Hoeft, and F. Stuber Rapid and Reliable Method for Cytochrome P450 2D6 Genotyping Clin. Chem., September 1, 2002; 48(9): 1412 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ji, S. Pan, J. Marti-Jaun, E. Hanseler, K. Rentsch, and M. Hersberger Single-Step Assays to Analyze CYP2D6 Gene Polymorphisms in Asians: Allele Frequencies and a Novel *14B Allele in Mainland Chinese Clin. Chem., July 1, 2002; 48(7): 983 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Kisabeth Laboratory Adaptations--Changing Expectations Clin. Chem., August 1, 2001; 47(8): 1509 - 1515. [Full Text] [PDF]
|
|
|
|
|
|
M. Hersberger, J. Marti-Jaun, K. Rentsch, and E. Hanseler Two Single-Tube Tetra-Primer Assays to Detect the CYP2C19*2 and *3 Alleles of S-Mephenytoin Hydroxylase Clin. Chem., April 1, 2001; 47(4): 772 - 774. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
